乳腺癌内乳淋巴结优化处理研究进展  

Optimization management of internal mammary lymph node in breast cancer

作　　者：毕钊 王永胜[1] Bi Zhao;Wang Yongsheng(Shandong Cancer Hospital and Institute,Shandong First Medical University(Shandong Academy of Medical Sciences),Jinan 250017,China)

机构地区：[1]山东省肿瘤防治研究院、山东第一医科大学、山东省医学科学院,济南250117

出　　处：《中华内分泌外科杂志（中英文）》2024年第5期605-608,共4页Chinese Journal of Endocrine Surgery

基　　金：中国博士后基金面上项目(2022M721987)。

摘　　要：目的内乳淋巴结(internal mammary lymph node,IMLN)和腋窝淋巴结均为乳腺癌转移的第一站淋巴结,其转移状况是确定分期和制订辅助治疗策略的重要依据之一。乳腺癌腋窝区域处理已趋于个体化,在优效全身治疗和精准放疗支持下,IMLN的微创诊断和精准处理再次受到关注。前哨淋巴结活检时代,需精准衡量乳腺癌患者所需的治疗强度,确立个体化IMLN处理策略,以达到乳腺癌区域淋巴结精准处理的目的。本文就乳腺癌内乳区域优化处理的最新进展进行总结,以期为广大临床工作者提供参考。Internal mammary lymph node(IMLN)and axillary lymph node are the first station for breast cancer metastasis.The status of IMLN is one of the prognostic factors in breast cancer patients and essential to regional staging and adjuvant treatment choice.The axillary treatment of breast cancer has become to be individualized.The minimally invasive diagnosis and precise management of internal mammary region received attention again with the improvements in optimal systemic therapy and precision radiotherapy.In the era of sentinel lymph node biopsy,we need to accurately measure the treatment intensity required by patients and establish an individualized IMLN treatment strategy,in order to achieve the purpose of accurate treatment of regional lymph nodes in breast cancer.This review evaluated the latest progress of precise regional processing of IMLN,in order to provide reference for clinical doctors.

关 键 词：乳腺癌 内乳淋巴结 前哨淋巴结活检 放疗 新辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]